Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy

WKM Liew, PB Kang - Therapeutic advances in neurological …, 2013 - journals.sagepub.com
Pediatric neuromuscular disorders comprise a large variety of disorders that can be
classified based on their neuroanatomical localization, patterns of weakness, and laboratory …

Functional and clinical outcomes associated with steroid treatment among non-ambulatory patients with Duchenne muscular dystrophy 1

CM McDonald, OH Mayer, KN Hor… - Journal of …, 2023 - content.iospress.com
Background: Evidence on the long-term efficacy of steroids in Duchenne muscular dystrophy
(DMD) after loss of ambulation is limited. Objective: Characterize and compare disease …

Emerging drugs for Duchenne muscular dystrophy

V Malik, LR Rodino-Klapac… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Duchenne muscular dystrophy (DMD) is the most common, severe childhood
form of muscular dystrophy. Treatment is limited to glucocorticoids that have the benefit of …

Molecular and clinical characteristics of a national cohort of paediatric Duchenne muscular dystrophy patients in Norway

EJ Annexstad, T Fagerheim, I Holm… - Journal of …, 2019 - content.iospress.com
Background: As new gene-related treatment options for Duchenne muscular dystrophy
(DMD) are being developed, precise information about the patients' genetic diagnosis and …

Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy

APQC Araujo, JAM Saute, CPDD Fortes… - Arquivos de Neuro …, 2023 - SciELO Brasil
In the last few decades, there have been considerable improvements in the diagnosis and
care of Duchenne muscular dystrophy (DMD), the most common childhood muscular …

Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options

A LoMauro, MG D'Angelo, A Aliverti - Therapeutics and clinical risk …, 2015 - Taylor & Francis
Duchenne muscular dystrophy (DMD) is an X-linked myopathy resulting in progressive
weakness and wasting of all the striated muscles including the respiratory muscles. The …

Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial

J Kirschner, J Schessl, U Schara, B Reitter… - The Lancet …, 2010 - thelancet.com
Background Duchenne muscular dystrophy is a rare X-linked progressive disease
characterised by loss of ambulation at about age 10 years, with death in early adulthood due …

Duchenne muscular dystrophy (Primer)

D Dongsheng, G Nathalie, M Eugenio… - Nature Reviews …, 2021 - search.proquest.com
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads
to difficulties with movement and, eventually, to the need for assisted ventilation and …

Duchenne muscular dystrophy

D Duan, N Goemans, S Takeda, E Mercuri… - Nature Reviews …, 2021 - nature.com
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads
to difficulties with movement and, eventually, to the need for assisted ventilation and …

Diagnosis of Duchenne muscular dystrophy in Italy in the last decade: critical issues and areas for improvements

A D'Amico, M Catteruccia, G Baranello, L Politano… - Neuromuscular …, 2017 - Elsevier
Despite all the advances in diagnosis and management of Duchenne muscular dystrophy
over the past 50 years, the average age at diagnosis in most countries in the world around is …